Medtronic’s MiniMed 780G System sets new standards in diabetes management

Medtronic plc (NYSE: MDT), a global frontrunner in medical technology, has recently unveiled compelling new clinical and real-world evidence regarding the MiniMed 780G system, marking a significant advancement in diabetes management technology. Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, this evidence underscores the system’s efficacy in enhancing Time in Range (TIR) metrics for users worldwide, including substantial findings from the United States.

The MiniMed 780G system, celebrated for its sophisticated design and capability to improve diabetes control, now boasts over 100,000 real-world users achieving an average TIR of 78% using recommended settings, surpassing the international TIR target of 70%. This achievement is built on the foundation of 3-year data published in Diabetes Technology & Therapeutics, which highlighted the system’s proficiency in maintaining optimal glucose levels.

Moreover, new data presented focused on the system’s ability to help users attain Time in Tight Range (TITR) goals, a cutting-edge metric reflecting glucose levels akin to individuals without diabetes. TITR emphasizes maintaining glucose levels within 70-140 mg/dL, aiming to reduce the upper threshold from the conventional 180 mg/dL to 140 mg/dL. Results reveal that users (n=13,461) have successfully achieved a TITR of over 56% with the MiniMed 780G, by setting a target glucose level of 100 mg/dL and an active insulin time of 2 hours. This data contributes to the emerging consensus that achieving a TITR of 50% or more is feasible with the right therapeutic approach.

Robert Vigersky, MD, Chief Medical Officer at Medtronic Diabetes, emphasized the critical link between increased TIR and reduced diabetic complications, highlighting the harmful impact of elevated glucose levels. He stated, “The preponderance of data across randomized controlled trials and real-world studies show that the MiniMed 780G system is maximizing Time in Range far surpassing international targets and is taking it a step beyond by getting people closer to euglycemia. In the absence of a cure, our goal is to relentlessly innovate therapies to help people maximize their health without adding burden, which our newest AID system has proven to do.”